Today's Healthcare Pulse
Allogene Therapeutics CEO David Chang to step down
Allogene Therapeutics announced that chief executive David Chang will leave his role. The news was reported by STAT+ and echoed in a follow‑up piece covering broader pharma updates.
Also developing:
By the numbers: Boston Scientific invests $1.5B for 34% stake in MiRus
Senior Lucy Letby Hospital Boss Arrested
A senior executive at the Countess of Chester Hospital was arrested on suspicion of perverting the course of justice, part of Cheshire Police's Operation Duet. The operation investigates both corporate manslaughter and gross negligence manslaughter linked to the 2023 convictions of nurse Lucy Letby for killing seven infants and attempting to kill seven more. Police have completed property searches but have not disclosed the arrested individual’s identity or the location. The arrest follows earlier 2025 detentions of three senior leaders under the same probe.
AI Chip Giant Outvalues Entire Global Pharma Industry
NVIDIA is now worth more than the entire Big Pharma combined on the stock market. I shared this image from Reza Zahiri, PhD, MBA, 6 months ago. NVIDIA’s market cap now hit $4.9 trillion ($0.3 trillion more than then), which...
HHS Launches $139.4 Million ARPA‑Health Initiative to Accelerate Behavioral‑Health Therapies
The U.S. Department of Health and Human Services' ARPA‑Health agency unveiled a $139.4 million research program aimed at rapid‑acting behavioral‑health treatments, earmarking at least $50 million to match state psychedelic research investments under a recent presidential executive order.
UNPACKING THE CHALLENGES FACING SOUTH AFRICA’S HEALTHCARE REFORM
South Africa’s post‑apartheid health system has shifted toward greater inclusivity, but stark gaps between public and private care persist. The National Health Insurance scheme, touted as a path to universal coverage, faces a Constitutional Court decision slated for May 2026, prompting...
Gravity Rail Raises $2.75M From Redesign Health for AI Patient Communication
Gravity Rail, an AI‑driven platform that automates patient calls, texts and follow‑up workflows, announced a $2.75 million seed round led by Redesign Health. The funding will accelerate product development and expand its go‑to‑market team. Gravity Rail’s technology aims to streamline enrollment,...
Infinitus Systems Launches “Studio”: The First No-Code AI Agent Builder Purpose-Built for Healthcare Complexity
Infinitus Systems has launched Studio, a no‑code AI agent builder designed specifically for healthcare. The platform lets operational teams create and deploy agents via a natural‑language interface, cutting deployment time by 90% and boosting accuracy 40% over manual methods. Its...
UFP Technologies: Great Growth At Just An Okay Price
UFP Technologies (UFPT) is delivering strong revenue and profit growth in the MedTech space, fueled by strategic acquisitions and expanding exposure to high‑growth areas such as robotic surgery and infection‑prevention products. The company benefits from a $550 billion MedTech market and...
Embryonic Smoothened Receptor Found to Tune Adult Learning and Flexibility
Scientists led by Kottmann and Santiago Uribe‑Cano have shown that the Smoothened receptor, known for embryonic development, controls the timing of dopamine and acetylcholine signals in the adult striatum. The discovery reveals a molecular “tuning knob” that balances reinforcement strength...
Mega fMRI Study Shows Psychedelics Collapse Brain Hierarchy, Offering Clues for Meditation Research
Researchers from UCSF, McGill and Cambridge pooled resting‑state fMRI data from more than 250 participants across seven labs and found that classic psychedelics collapse the brain's usual hierarchy between abstract thinking and sensory perception. The unified analysis, published in Nature...
Algeria Eliminates Trachoma as a Public Health Problem
The World Health Organization has officially validated Algeria’s elimination of trachoma as a public health problem, making it the 10th country in the African Region and the 29th worldwide to achieve this status. Trachoma, the leading infectious cause of blindness,...
AI‑Enabled Strategies Target Healthspan as Experts Map Path to 200‑Year Lifespans
On April 23, 2026, leading aging researchers released an analysis highlighting AI‑driven approaches—senolytics, NAD+ precursors and metabolic drugs—to extend healthspan and potentially enable 200‑year lifespans. The report stresses mechanistic rigor, public‑private funding, and the need for combination therapies.
FDA Expands Sanofi's Tzield to Children as Young as One, Delaying Type 1 Diabetes Progression
The U.S. FDA approved Sanofi's Tzield for children aged one to seven with stage 2 type 1 diabetes, extending its indication beyond the previous eight‑year‑old threshold. Backed by the PETITE‑T1D phase 4 study, the move gives families a new tool to postpone the...
Regeneron and Sanofi Report the US FDA Approval of Dupixent (Dupilumab) for Chronic Spontaneous Urticaria (CSU)
Regeneron and Sanofi announced that the U.S. Food and Drug Administration has approved Dupixent (dupilumab) for chronic spontaneous urticaria (CSU) in patients as young as two years old who remain symptomatic despite H1 antihistamines. The decision is based on two...
85-Year-Old VK Digital Health CEO Prepares Seed Round to Fund 2,500 Smart Clinics
Charlie Nahabedian, the 85‑year‑old founder and CEO of VK Digital Health, is gearing up for a seed‑stage financing round that will finance the rollout of smart clinic chairs and mobile health units to 2,500 sites. The company has already raised...
The Field of Dermatology Is Undergoing a Transformation
Dermatology is shifting from purely cosmetic, marketing‑driven procedures to science‑based longevity treatments that target the underlying mechanisms of skin aging. New therapies that clear senescent cells, modulate epigenetic clocks, and employ partial cellular reprogramming are delivering measurable improvements in barrier...
13,000+ England A&E Patients Wait Over 72 Hours, Sparking Reform Calls
New BMJ data shows more than 13,000 patients waited at least three days in England’s A&E departments in 2025, while half a million faced 24‑hour waits. The figures have intensified pressure on Health Secretary Wes Streeting and clinicians to overhaul...
Medicare Steps Up on Obesity Care. Will Health Insurers?
The Centers for Medicare & Medicaid Services (CMS) announced an extension of its GLP‑1 Bridge program through 2027, offering seniors obesity drugs at a $50 monthly copay. The bridge operates outside Medicare Part D, removing financial risk for private insurers. CMS...
Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins
Dexcom (DXCM) is positioned to profit from the booming weight‑loss drug market, as GLP‑1 therapies drive both new diabetes diagnoses and higher CGM adoption among patients. The company reports faster CGM usage growth among GLP‑1 users and highlights a still‑under‑penetrated...
How Employers End up Paying for Weight Gain
Employers are rapidly adding GLP‑1 weight‑loss drugs to health plans, but more than half of participants abandon therapy within a year, eroding the expected return on investment. While some firms pair prescriptions with nutrition coaching and behavior‑change programs, only about...
Oura’s Strategic Acquisition of Galen AI and the Future of Personal Medical Sovereignty
On April 17, 2026 Oura Health announced the acquisition of Galen AI, a Stanford‑born startup that unifies fragmented medical records via FHIR. The deal expands Oura’s smart ring from a fitness tracker to a connected health companion that can cross‑reference...
/file/attachments/orphans/Image-1-Bukhosi-Mdletshe_405154.jpg)
SPOTLIGHT: ‘I’m Serving My People’: The Pastor Running a Rural Clinic that Treats More than Illness
Bukhosi Mdletshe, a pastor and operational manager of Ensingweni Clinic in KwaZulu‑Natal’s King Cetshwayo District, oversees a rural health hub serving roughly 12,000 people spread across a 60‑km area. The clinic combines basic medical services with proactive home‑based care, deploying...
Novo Nordisk’s Oral Semaglutide Demonstrates Potential to Be the First Oral GLP-1 RA Therapy for Children and Adolescents with Type...
Novo Nordisk reported positive topline results from the phase 3a PIONEER TEENS trial, the first study of an oral GLP‑1 receptor agonist in children and adolescents with type 2 diabetes. Oral semaglutide lowered HbA1c by 0.83 percentage points versus placebo...
Are You Waiting for Opioid Settlement Money From Purdue, Mallinckrodt or Endo? Get in Touch.
ProPublica and The Philadelphia Inquirer are probing how victims of the U.S. opioid crisis are being compensated under the bankruptcy settlements of Purdue Pharma, Mallinckrodt and Endo. A recent investigation highlights that Purdue’s revised bankruptcy plan trims payouts and omits...
ASCO Grants IDYA Late‑breaker Despite Extensive Prior Data
Given how much $IDYA has already released (ORR, PFS, stats, PFS curves) I'm a little surprised #ASCO26 is OK with giving it a late-breaker.
How AI and Robotics Designed New Cancer Therapies
In this episode, Angus Sinclair, CSO of LabGenius Therapeutics, explains how their AI‑driven AVA platform combines high‑throughput cell‑based assays with machine learning to design non‑intuitive protein therapeutics, specifically T‑cell engagers for solid tumors. He details the challenges of targeting antigens...
OpenAI Launches ChatGPT for Clinicians
OpenAI unveiled ChatGPT for Clinicians, a medically‑tuned version of its GPT‑5.4 engine aimed at individual health providers. The service is free for verified U.S. physicians, nurse practitioners, physician assistants and pharmacists, and offers higher usage limits, workflow‑specific skills, and a...
Merck & Co., Inc. (MRK) Gains FDA Priority Review for KEYTRUDA Regimen in Muscle-Invasive Bladder Cancer
Merck announced that the U.S. FDA has granted Priority Review to two supplemental Biologics License Applications for KEYTRUDA and KEYTRUDA QLEX, each combined with Padcev, targeting muscle‑invasive bladder cancer patients eligible for cisplatin chemotherapy. The agency set an action date...
Operational Lessons From Global Nephrology Trials
The article outlines four operational lessons drawn from the surge of global nephrology trials, noting that GlobalData tracks 888 CKD studies with only 56 multinational efforts. It argues that traditional site selection in Europe and the U.S. limits enrollment speed...
Could Anemia Increase the Risk of Developing Dementia?
A Swedish cohort of 2,282 adults aged 60+ was followed for up to 16 years to examine anemia’s link to dementia. Researchers found that baseline anemia raised the risk of developing dementia by 66 % compared with normal hemoglobin levels. The...
WHO Reports Measurable Health Impact in 2025 Amid Transition to New Strategy
The World Health Organization released its 2025 Results Report, the final assessment of its Thirteenth General Programme of Work, showing measurable progress across the Triple Billion targets despite funding cuts. Compared with a 2018 baseline, an extra 567 million people accessed...
Rheumatology For Physiotherapists: A Guide For Students And New Grads
The blog promotes a podcast‑style video where Jack March breaks down rheumatology for physiotherapy students and new graduates. It explains how to differentiate systemic inflammatory conditions from typical musculoskeletal issues using screening questions, comorbidity clues, and clinical reasoning. The episode...
RG6735 Identified as New $RHHBY Phase‑1 Asset
Any idea what RG6735 is? Looks like a new $RHHBY code for sth that went into phase 1 earlier under a different name. https://t.co/7Cb5Ft2BWC
FDA Grants Clearance for Philips’ Rembra Scanning Platform
Philips has secured FDA 510(k) clearance for its Rembra platform, encompassing the Rembra CT scanner, Rembra RT and Areta RT radiation‑therapy systems. The CT unit features an 85 cm bore and can handle up to 270 exams per day, targeting high‑throughput...
ModeX Starts Dosing in MDX2003 Trial for B-Cell Lymphoma
ModeX Therapeutics, an OPKO Health subsidiary, has begun dosing the first patients in the MDX‑2003‑101 trial of its tetraspecific T‑cell engager MDX2003 for relapsed or refractory B‑cell lymphoma. The study will evaluate tolerability, pharmacokinetics, safety and immune activity across dose‑escalation...
Epitopea Wins UK Approval for Therapeutic Vaccine Trial
Epitopea secured UK regulator and ethics committee clearance to launch OVACT, a Phase I/Ib first‑in‑human trial of its RNA‑based vaccine CryptiVax‑1001 in advanced high‑grade serous ovarian cancer. The study will evaluate safety, tolerability, immunogenicity and early clinical activity in HRP⁺/BRCA‑wildtype...
New Case Law Could Put Radiologists on Hook for Imaging-Order Appropriateness
A 2025 Ohio appellate decision, Kelley v. Horton, allowed the American College of Radiology’s Appropriateness Criteria to be used in a malpractice trial, marking the first time the guidelines were admitted as evidence. The case involved two MRIs ordered by...
Sex‑disaggregated Data Crucial, yet Underused in Women's Health
Uncharted: understanding women’s health across the body Disaggregating data by sex is a powerful way to help develop better diagnostics and treatments for women — but researchers say it’s not used enough. https://t.co/7TeEYN4yPf https://t.co/95VdJKI05c
Interventional Radiologists Launch New Chain of Standalone Outpatient IR Centers
Two California interventional radiologists have launched Elmnt IR, a chain of standalone outpatient interventional radiology centers, beginning with a flagship location in Los Angeles. The venture targets high‑impact conditions such as benign prostatic hyperplasia, uterine fibroids, knee osteoarthritis, and select...
AstraZeneca Reports the P-III (I CAN) Trial Data on Ultomiris for IgA Nephropathy
AstraZeneca announced interim Phase III (I CAN) data for Ultomiris in IgA nephropathy, enrolling about 510 high‑risk adults. The trial met its primary endpoint, showing a roughly 30% reduction in 24‑hour proteinuria at 34 weeks, with benefits evident as early as 10...
Voice Therapy App Improving Outcomes for Parkinson’s Patients at University Hospitals of Derby and Burton
University Hospitals of Derby and Burton introduced a voice‑therapy app for Parkinson’s patients, enabling home‑based exercises after an initial in‑person assessment. The pilot saved 14‑17 hours of clinical time each month, equivalent to six extra therapy slots per week, and...
Mainetti Launches MAMI – A Non-Profit Initiative Supporting Premature Infants in Neonatal Intensive Care Units Across Italy
Mainetti Italia and the Cuore di Maglia Association have launched MAMI, a non‑profit initiative that supplies CE‑certified therapeutic fabric gloves to premature infants in neonatal intensive care units (NICUs) across Italy. The gloves, made from fire‑proof fabric and polypropylene granules,...
Trelleborg Costa Rica Site Earns ISO 13485 Certification
Trelleborg Medical Solutions' Costa Rica manufacturing site earned ISO 13485:2016 certification, confirming its quality management for medical devices. The 107,600‑sq‑ft facility, opened in December 2025 in the Evolution Free Zone, is the company’s first Central American plant and supports nearshoring and supply‑chain...
ICR Bolsters Healthcare Unit
ICR announced two senior hires to strengthen its healthcare communications franchise: John Capodanno was named head of U.S. healthcare corporate communications, and Matthew Willey was appointed managing director of the medical‑technology and diagnostics practice. Capodanno brings over 25 years of...
Utepreva Launches Utepreva Endometrial Sampler to Support Early Diagnosis of Endometrial Cancer
Utepreva has introduced the Utepreva Endometrial Sampler, a single‑use device aimed at improving tissue capture for early endometrial cancer diagnosis, slated for market release in October 2026. The sampler integrates a sponge tip, plunger‑driven suction, and a collection chamber to...
CEPI Shows Courage; Institutions Must Follow Suit
Many institutions are failing to meet the moment, but not all. @CEPIvaccines proves it has the courage & conviction to carry out essential vaccine work regardless of political pressure for complicity. I wish more institutions would follow their funder’s example.
Fraunhofer IAP and NMI Achieve Biomimetic Tissue Mechanics
Fraunhofer IAP and NMI have created a patent‑pending biomimetic tissue substitute that combines a polyurethane acrylate base, a 3D‑printed wavy metastructure, and an electrospun collagen surface. The metastructure reproduces the nonlinear stiffness of pericardial tissue, while the collagen layer supports...
ViewsML Closes Funding Round to Accelerate Commercialization of AI-Driven Virtual Biomarker Staining Platform
ViewsML announced an oversubscribed $4.9 million seed round led by Wittington Ventures, with new investors Mayo Clinic and Continuum Health Ventures joining repeat backers. The capital will fast‑track commercialization of its AI‑driven virtual biomarker staining platform, which extracts per‑cell biomarker insights...
Iran War Pushing up Till Price of some Drugs by up to 30%, Pharmacies Warn
The Iran‑U.S. conflict has driven up fuel and air‑freight costs, pushing wholesale drug prices in England up 40‑50%. Community pharmacies now charge 20‑30% more for over‑the‑counter painkillers and hay‑fever tablets, with a 100‑tablet pack of paracetamol rising from £0.41 ($0.52)...
Engineering Insights: Polyimide, PTFE & Reinforced Tubing for Next-Gen Devices
MicroLumen’s white paper spotlights polyimide and PTFE‑polyimide composite tubing as pivotal for next‑generation catheters. The thermoset polyimide delivers unmatched dimensional stability under mechanical and thermal loads, while PTFE adds low‑friction surfaces. Engineers can tailor torque, pushability, and flexibility through braided...
Defending TrumpRx Scam, RFK Jr. Absurdly Claims Trump ‘Has His Own Way of Calculating’ Percentages
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. defended President Donald Trump’s claim that prescription‑drug prices were cut by 600%, arguing the president uses a different way to calculate percentages. In a Senate Finance Committee hearing, Senators Elizabeth...